Okragly et al. showed the complete neutralization of IL-33 activity in vitro and in vivo in cynomolgus monkeys; hence, great hopes are associated with this drug and its use to treat atopic dermatitis in clinical trials [141]. Here, IL33 is linked to atopic eczema.